I'd given myself the best possible chance to delay it
For over a century, a diagnosis of type 1 diabetes has carried with it an unspoken sentence: a lifetime bound to insulin. Australia's Therapeutic Goods Administration has now approved Tzield, a drug that intervenes before that sentence is fully handed down — preserving the body's own capacity to produce insulin by shielding the pancreas from immune attack. In a country that bears one of the world's heaviest burdens of this disease, the approval opens a door that medicine has been searching for since insulin itself was discovered.
- For the first time, a non-insulin treatment can interrupt type 1 diabetes before symptoms emerge, targeting the immune assault on the pancreas rather than compensating for its aftermath.
- An estimated 25,000 Australians are unknowingly living in the early stages of the disease right now — a silent population for whom this two-week treatment could mean years free from needles and pumps.
- A nineteen-year-old trial participant, watching her younger sister navigate a childhood reshaped by insulin dependency, chose to act — describing the treatment not as a cure but as reclaiming agency over her own future.
- The drug is approved for patients aged eight and older at stage two of the disease, but access and awareness remain the next frontier — thousands who could benefit may never know they are eligible in time.
For more than a century, type 1 diabetes has meant insulin — the nightly pumps, the daily injections, the unrelenting arithmetic of blood sugar. That reality is beginning to shift for Australians.
The Therapeutic Goods Administration has approved Tzield, developed by Sanofi, which works by binding to immune cells and preventing them from destroying the pancreas. If the pancreas is spared, it continues producing its own insulin. The drug is approved for patients aged eight and older who have reached stage two of the disease — when the immune attack has begun but symptoms have not yet surfaced. Around 25,000 Australians are estimated to be living in this window without knowing it, in a country that records roughly 3,000 new diagnoses each year.
Jessica Kovacs enrolled in the clinical trial at Royal Melbourne Hospital at nineteen, shaped by years of watching her younger sister Annabelle manage the disease since childhood — the hospital visits, the pump that monitored through the night, the interrupted ordinary life. The treatment was a two-week course of daily infusions. What it gave her was harder to measure than a blood sugar reading. "Before treatment, I felt like I was just waiting for T1D to strike," she said. "Afterwards, I felt like I'd done something proactive."
Endocrinologist Dr. John Wentworth, who administered the drug to trial participants, calls this the beginning of a transformation a hundred years in the making. A fortnight of treatment to potentially defer decades of insulin dependency is, he argues, a profound exchange — one that preserves not just the pancreas, but freedom. The question that now presses is whether the Australians living unknowingly in that early window will be found in time to benefit.
For more than a century, type 1 diabetes has meant one thing for patients: insulin. Daily injections, insulin pumps that beep through the night, the constant arithmetic of blood sugar management. That calculus is about to change for thousands of Australians.
The Therapeutic Goods Administration has approved Tzield, a drug that does something insulin cannot—it stops the disease before it fully takes hold. The medicine, developed by Sanofi, works by binding to specific immune cells and preventing them from attacking the pancreas. If the pancreas survives that assault, it can keep making its own insulin. For patients in the early stages of type 1 diabetes, this means years without needles, without pumps, without the daily vigilance the disease demands.
More than 145,000 Australians living with type 1 diabetes could eventually benefit. The drug is approved for patients aged eight and older who have progressed to stage two of the disease—the point at which the immune system has begun its attack but symptoms have not yet emerged. An estimated 25,000 more Australians are living unknowingly in these early stages right now. Australia carries one of the world's highest burdens of type 1 diabetes, with roughly 3,000 new diagnoses each year.
Jessica Kovacs was nineteen when she enrolled in the clinical trial at Royal Melbourne Hospital in January. Her sister Annabelle had been diagnosed at seven, and Jessica had watched what that meant: hospital visits, an insulin pump that never stopped monitoring, a childhood interrupted by the machinery of disease management. When the opportunity came to try Tzield, she took it. The treatment itself was straightforward—a two-week course of daily infusions through a catheter. What came after was harder to quantify. "Before treatment, I felt like I was just waiting for T1D to strike," Kovacs said. "But afterwards, I felt like I'd done something proactive. I'd given myself the best possible chance to delay it."
Dr. John Wentworth, the endocrinologist who administered the drug to Kovacs and other trial participants, frames this moment as the beginning of a transformation that has been a hundred years in the making. Insulin, he notes, is an imperfect tool—effective, yes, but demanding. A two-week treatment to potentially avoid decades of daily injections is, by that measure, a bargain. "It just gives you the freedom and far better health outcomes by delaying and not having to use insulin because your pancreas has been preserved," Wentworth, a clinical fellow at St Vincent's Institute of Medical Research, told the Australian Associated Press.
The approval marks a threshold moment in how medicine approaches type 1 diabetes. For the first time, there is a way to intervene before the disease fully declares itself, to preserve the body's own insulin-producing capacity rather than simply replacing what has been lost. For families like the Kovacs household, where type 1 diabetes has already reshaped one child's life, the existence of such an option—even if it comes too late for them—carries its own weight. The question now is how quickly this treatment reaches the thousands of Australians who are unknowingly living in the window where it could make a difference.
Notable Quotes
This is the start of the revolution that has been a century in the making to find better ways to treat type 1 diabetes— Dr. John Wentworth, endocrinologist at St Vincent's Institute of Medical Research
It just gives you the freedom and far better health outcomes by delaying and not having to use insulin because your pancreas has been preserved— Dr. John Wentworth
The Hearth Conversation Another angle on the story
Why does this matter so much? Insulin works. People with type 1 diabetes manage it every day.
Insulin works, but it's a substitute, not a cure. You're replacing something your body should be making. This drug tries to stop the immune system from destroying the cells that make insulin in the first place. That's a fundamentally different approach.
So it's not for people who already have diabetes?
No. It's for people in the early stages, before symptoms show up. There's a window where the immune attack is happening but the pancreas still has some function left. If you can stop that attack in those early months or years, the pancreas keeps working on its own.
How many people are in that window?
About 25,000 Australians don't even know they're there. They could get diagnosed tomorrow, or in five years. This drug could delay that, maybe for years.
What's the catch?
It's a two-week treatment with daily infusions. That's not nothing. But if it buys you five years without insulin needles, or ten years, most people would take that trade.
And the girl in the story—Jessica—did it work for her?
We don't know yet. That's the thing about this drug. You won't know if it worked until time passes and you don't get sick. She's betting on a future that hasn't happened yet.